Igc Pharma (IGC) Stock
Small cap pharmaceutical company developing new drug candidates. Here's the price, business snapshot, and what's worth knowing about Igc Pharma in October 2026.
IGC Pharma Inc (IGC) is a small-cap pharmaceutical company with a market capitalisation of approximately $35.9 million. As a company operating in the pharmaceutical sector, it is likely focused on research, development and commercialisation of drug candidates or related technologies; investors should consult company filings for precise details on its pipeline and strategy. Micro-cap stocks such as IGC can offer meaningful upside if clinical or commercial milestones are met, but they also carry heightened risks: limited liquidity, wide price swings, and potential need for additional funding that can dilute shareholders. Typical investor considerations include the stage of development, cash runway, partnerships, regulatory progress and management track record. This overview is educational only and not personal financial advice; IGC may suit risk-tolerant investors with a long-term horizon, but it may be inappropriate for those needing capital preservation or low volatility.
Igc Pharma (IGC) Stock Forecast
Analyst price target, next 12 months
$4.00
+1526.0% vs today's $0.25
Price range over the last 12 months
Close to its 12-month low
Analysts covering Igc Pharma have a consensus 12-month target of $4.00, above the current price of $0.25.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying IGC Pharma's stock, with a target price of $4, indicating significant growth potential.
Financial Health
IGC Pharma has low revenue and cash flow, indicating challenges in generating profits.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Microcap market dynamics
A market cap near $36m can provide meaningful upside if milestones are hit, though expect higher volatility and reduced liquidity compared with larger stocks.
R&D catalysts and trials
Clinical or regulatory progress tends to be a primary value driver for pharma firms; outcomes are often binary and can move the share price sharply.
Funding and partnerships
Smaller pharmaceutical companies commonly rely on partnerships or capital raises to advance programmes, which can dilute holders but also de‑risk development if done strategically.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
